*Corresponding Author:
M. R. Talluri
ACR Laboratories, Ramanthapur, Hyderabad-500 013, India
E-mail: [email protected]
Date of Submission 25 December 2018
Date of Revision 28 March 2019
Date of Acceptance 23 June 2019
Indian J Pharm Sci 2019;81(4):747-756  

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

Abstract

The current study was aimed to develop and validate a simple and sensitive method to quantify valganciclovir and its metabolite ganciclovir in human plasma using valganciclovir-D5, ganciclovir-D5 as internal standards for pharmacokinetic analyses. The method exhibited highly sensitive ranges 2-805 ng/ml for valganciclovir and 40-12000 ng/ml for ganciclovir. The analytes were extracted from plasma using solid phase extraction employing mixed-mode cation exchange cartridges. Valganciclovir and ganciclovir were separated using Agilent XDB-Phenyl column with a mobile phase consisting 35:65 ratio of 10 mM ammonium acetate in 0.3 % formic acid and acetonitrile at 0.60 ml/min flow rate with 2.50 min run time. The validated parameters were within the acceptance criteria as per the regulatory guidelines and the validated calibration curve (CC) ranges to both analytes have r value >0.99 with above 90 % recovery. The validated method was successfully used to study pharmacokinetics of orally administered valganciclovir (900 mg) in healthy male volunteers. The pharmacokinetic parameters were, Cmax 300 ng/ml for valganciclovir and 6000 ng/ml for ganciclovir, and tmax 0.50 h for valganciclovir and 1.00 h for ganciclovir.

Keywords

Valganciclovir, ganciclovir, plasma, metabolite, deuterated, recovery, pharmacokinetics

The discovery and development of new drugs involved many vital processes such as drug identification, isolation, synthesis and analysis[1]. The analysis part is most important and very difficult for new drugs because, the results indicate their purity, quantification and interpretation of these data play key role in identification and estimation of their pharmacological activity[2,3]. In last few decades, several new diseases have emerged like Ebola and some diseases have become untreatable[4,5]. This situation prompted the researchers to discover new drugs and new analytical methods to identify accurately with reliable certainty[6]. In the present-day viral infections fall under this situation, because these affect epidemically and pandemically the population around the world[7,8].

Valganciclovir (VAL) is one of the antiviral drug to treat the cytomegalovirus (CMV) infections in acquired immune deficiency syndrome (AIDS) patients for retinitis and in organ transplantation condition to prevent CMV infections[9,10]. VAL is a prodrug for ganciclovir (GAN), which is an analogue for 2’-deoxyguanosine and the deoxyribonucleic acid (DNA) synthesis is terminated by inhibiting the DNA polymerase enzyme in CMV by replacing the 2’ deoxyguanosine triphosphate[11-14]. The World Health Organization (WHO) added VAL as essential medicine as an effective and safe medicine needed for human wealth[15]. Recently, US FDA approved the manufacturing of generic VAL but the available analytical methods for VAL are not suitable to quantify in different biological matrices. There are some early reports on bio-analytical methods for VAL, GAN but, they are old, were analysed with nondeuterated drugs as internal standards (IS) and are not sensitive[16-19]. The high accuracy results are very important in quantification of drugs using IS through liquid chromatography with tandem mass spectrometry (LC-MS-MS), use of stable isotope labelled ISs usage provides the accurate results and reduces the variations in MS[20,21]. So, the current study was aimed to develop new bio-analytical method with deuterated drugs as IS for VAL and GAN in human plasma and its validation as per regulatory guidelines (US FDA).

Materials and Methods

The solvents used in the current investigation were LCMS grade (J.T. Baker, USA). Analytical grade formic acid (98-100 %) was from Merck (Mumbai, India). Standard VAL, GAN, GAN D5 were procured from Vivan Life Sciences (Mumbai, India) and VAL D5 was procured from Clear Synth Labs (Mumbai, India). The human plasma with K2 EDTA as anticoagulant was obtained from Deccan Pathological Laboratory (Hyderabad, India). The LC-MS-MS used was equipped with an LC system from Shimadzu (Japan) and API-4000 MS-MS from Sciex (USA); XDB Phenyl 4.6×75 mm (Make- Agilent) column was used.

Standard and internal standard stock solution:

VAL stock solution (1 mg/ml) was prepared in methanol and GAN, GAN D5, VAL D5 were also prepared as 1 mg/ml solutions in dimethyl sulphoxide. These stock solutions were used for further dilutions with 50 % acetonitrile (ACN) in HPLC grade water (diluent) to prepare calibration curve and quality control (QC) samples. The calibration curve points were ten nonzero concentrations with range 2.04-805.35 ng/ml for VAL and 40.41-12097.57 ng/ml for GAN and QCs were 2.05 ng/ml (lower limit of quantification quality control, LLOQ QC), 6.01 ng/ml (lower quality control, LQC), 125.28 ng/ml (middle quality control 1, MQC1), 377.35 ng/ml (middle quality control 2, MQC2), and 566.56 ng/ml (high quality control, HQC) for VAL and 40.43 ng/ml (LLOQ QC), 121.04 ng/ml (LQC), 1806.56 ng/ml (MQC1), 6021.89 ng/ml (MQC2), and 9041.88 ng/ml (HQC) for GAN as final concentrations in blank plasma spiked as 5 % from 20 times working concentrations prepared with diluent using standard stock solutions. Dilution integrity (DI) samples were prepared by spiking 3.10 times (2495.07 ng/ml of VAL and 3.16 times of 38205.11 ng/ml of GAN) of the highest standard concentration. These spiked samples were stored at –70° and 12 sets of LQC and HQC at –20° for further validation study.

LC-MS/MS method optimization:

The separation and quantification of VAL and GAN were carried out using LC-MS/MS with positive and negative ionization modes, finally fixed to positive ion mode with different mass optimization parameters such as the curtain gas (CUR) and collision energy (CE) for VAL and GAN. The final optimized parameters for mass spectrometry are shown in Table 1. Separation of the two analyte from the same sample is always difficult using LC at different concentrations of analytes but VAL and GAN were separated successfully with good response even at low concentrations. The optimized chromatographic conditions are listed in Table 2.

Parameter Valganciclovir Valganciclovir D5 Ganciclovir Ganciclovir D5
Detection m/z 355.10 (parent) and 152.10 (product) 360.10 (parent) and 152.10 (product) 256.10 (parent) and 152.10 (product) 261.10 (parent) and 152.10 (product)
Ion Spray Voltage (IS) 5500.00 V 5500.00 V 5500.00 V 5500.00 V
Temperature (°) 550.00 550.00 550.00 550.00
Curtain Gas (CUR) 25.00 psi 25.00 psi 25.00 psi 25.00 psi
Collision Gas (CAD) 6.00 psi 6.00 psi 6.00 psi 6.00 psi
GS1 30.00 psi 30.00 psi 30.00 psi 30.00 psi
GS2 35.00 psi 35.00 psi 35.00 psi 35.00 psi
Declustering Potential (DP) 70.00 V 70.00 V 90.00 V 66.00 V
Collision Energy (CE) 28.00 V 28.00 V 21.00 V 22.00 V
Collision Cell Exit Potential (CXP) 12.00 V 10.00 V 10.00 V 10.00 V
Entrance Potential (EP) 10.00 V 10.00 V 10.00 V 10.00 V
Dwell time (ms) 200 200 200 200

Table 1: Optimized mass spectrometry parameters

Column XDB Phenyl 4.6×75 mm (make-Agilent)
Rinsing solution Acetonitrile and water (50:50 % v/v)
Mobile phase LCMS grade acetonitrile: 10 mM ammonium acetate in 0.3 % formic acid (65:35, v/v)
Flow rate 0.600 ml/min
Sample cooler temperature
Column Oven Temperature 40°
Injection volume 10 µl
Retention time (RT) Valganciclovir 1.67±0.5 min
Valganciclovir D5 1.67±0.5 min
Ganciclovir 1.60±0.5 min
Ganciclovir D5 1.60±0.5 min
Run Time 2.50 min

Table 2: Optimized liquid chromatography parameters

Sample preparation:

The solid phase extraction (SPE) method was used to extract the drugs from plasma samples. About 250 μl of the plasma sample was pipetted into pre-labelled RIA vials, which contained 25 μl of ISs dilution (from working concentrations, 5000 ng/ml of VAL D5 and 10000 ng/ml of GAN D5), except in blank plasma samples where 25 μl diluent was added and then samples were vortexed. Then, 200 μl of 2 % orthophosphoric acid (OPA) buffer was added and vortexed. The sample mixture was loaded onto Strata™-X-C, 33 μ strong cation cartridges (30 mg/ml), pre-conditioned with 1.0 ml methanol, followed by 1.0 ml water. After applying maximum pressure, the extraction cartridge was washed with 1.0 ml of 2 % OPA buffer and followed by 1.0 ml of 5 % methanol in water. Then, the sample was eluted with 1.0 ml of 5 % ammonia in methanol. The samples were the evaporated to dryness at 50° in turbo evaporator under nitrogen gas and reconstituted the residue with 500 μl of mobile phase and vortexed. The reconstituted samples were centrifuged at 4000 rpm at 4° for 5 min and transferred into vials and loaded on to the auto sampler.

Method validation:

The developed method for quantification of VAL and GAN was validated as per USFDA guidelines[22]. The method validation included determination of sensitivity, selectivity, matrix effect (ME), linearity, accuracy, precision, recovery, DI, run size evaluation (RSE) and stability (room temperature, RT (20±5°) stock solution stability, refrigerated stock solution stability at 2-8°, freeze-thaw stability, bench top stability, short-term plasma samples stability at 20±5°, wet extract stability at 20±5º and auto sampler stability (AS).

The sensitivity was measured to check back noise by spiking 6 LLOQ QC samples. Ten lots of blank plasma samples including lipemic and haemolytic were used for selectivity and ME was checked. Linearity was checked with in the concentration range of 2.04 to 805.35 ng/ml for VAL and 40.41 ng/ml to 12097.57 ng/ml for GAN with 6 replicates of 5 different QC samples (LLOQ, LQC, MQC1, MQC2 and HQC). Precession was measured with percent coefficient of variance using concentrations of QC samples. Accuracy was expressed in percent for an absolute ratio of the mean value of calculated concentration of LLOQ, LQC, MQC1, MQC2 and HQC samples to their nominal values. Recovery of VAL, GAN and their ISs were determined by comparing the areas of extracted 6 replicates at LQC, MQC2 and HQC levels with post spiking blank plasma. The DI was performed with 3.10 times of VAL (2495.07 ng/ml) and 3.16 times of GAN (38205.11 ng/ml) for 4 times dilution. The RSE was performed with 40 sets of each LQC, MQC1, MQC2 and HQC with freshly prepared CCs and six sets of QCs.

Stability is very important in quantification of any drugs in aqueous or in different biological matrices. Stability studies for VAL and GAN in the developed method were carried out at different conditions; re-injection stability was checked for retention of already injected samples stability in auto sampler, AS was checked for the retention of processed samples, which were kept in auto sampler for analysis, wet extract stability was carried to know the stability of processed samples at RT, bench-top stability was carried to express the stability of drugs in spiked plasma after thawing, shortterm stability was carried to know the stability of drugs in spiked plasma at –20° because usually spiked plasma samples were stored at –70°, whole blood stability was studied to check the stability of drug in blood at RT and freeze-thaw stability was done to provide the number of freeze-thaw cycles for processing of spiked plasma.

Data processing:

Analyst 1.6.3 software was used for the chromatograms were acquired and processed by peak area ratio. The concentration of the unknown was calculated from the following Eqn. using regression analysis of spiked standard with the reciprocal of the square of ratio of the drug concentration to internal standard concentration as a weighting factor (1/concentration ratio)×2, y=mx+c, where, y is peak area ratio of VAL and GAN to IS; m is the slope of the calibration curve, x is the concentration of VAL and GAN (ng/ml), and c is y-axis intercept of the calibration curve.

Clinical application:

The developed and validated method was applied in a clinical study on 6 healthy volunteers for pharmacokinetic study by giving 900 mg of oral solution dosage (50 mg/ml) as approved by ethical committee (MAARG Independent Ethics Committee, Hyderabad). The study conducted on fasting conditions and blood samples (6 ml at each time-point) were collected in K2 EDTA vacutainer collection tubes (BD franklin, NJ, USA) at pre-dose (0 h), 0.167, 0.33, 0.50, 0.67, 0.83, 1.0, 1.25, 1.50, 1.75, 2.0, 2.25, 2.50, 2.75, 3.0, 3.33, 3.67, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0 14.0, 16.0, 24.0 and 36.0 h. After collection, sample were centrifuged at 4000 rpm for 5 min and then plasma samples were immediately stored at –70±10° for further use. These samples were analysed as unknown samples along with validated CC ranges of VAL, GAN and QCs as known samples. WinNonlin Professional software version 6.4 was used to calculate pharmacokinetic parameters of the samples. After sample analysis incurred, sample reanalysis (ISR) was carried out to verify the reliability of validated method.

Results and Discussion

Method development involved the detection of ions of VAL, GAN and their ISs using mass spectrometry, separation using LC and extraction of VAL and GAN from plasma using SPE. Before finalizing the above mentioned mass optimized parameters (Table 1), both the drugs were monitored under positive and negative ionization modes, a good response was observed under positive ionization mode, multiple reaction monitoring (MRM) technique was used to monitor the ion transitions. The m/z transition ions for VAL 355.100→152.100, GAN 256.100→152.100, VAL-D5 360.100→152.100 and GAN-D5 261.100→152.100 (Table 1, figs. 1a and 1b). After MRM finalization, different mobile phases were used like combinations of methanol, ACN with buffer (ammonium acetate, ammonium formate, formic acid) additions and pH adjustments and columns of different make like C18, C8, phenyl of Kromosil, Agilent, Thermo Scientific, Zodiac, ACE 5 Phenyl for separation of VAL and GAN. The good peak shape, consistency and reproducibility was observed in mobile phase i.e. 35:65 (v/v) ratio of 10 mM ammonium acetate in 0.3 % formic acid and ACN with XDB Phenyl (75 mm×4.6 μ) at flow rate of 0.60 ml/min (Table 3).

Name of the analyte Absence of matrix Presence of matrix
(IS normalized matrix factor)
LQC HQC LQC HQC
Valganciclovir 0.02# 1.74# 0.98±0.02* (2.04) 0.99±0.02* (1.68)
Ganciclovir 0.05# 4.35# 0.92±0.04* (3.98) 0.93±0.02* (1.68)

Table 3: Effect of the absence and presence of matrix on valganciclovir and ganciclovir

pharmaceutical-sciences-valganciclovir-ganciclovir

Figure 1: Mass transition ions spectra of valganciclovir and ganciclovir
A. valganciclovir, B. valganciclovir D5, C. ganciclovir and D. ganciclovir D5

After optimization of LC-MS/MS method, different extractive methods like SPE, protein precipitation (PPT) and liquid-liquid extraction (LLE) were used to extract drugs (VAL and GAN) from plasma. The SPE procedure gave better results compared to LLE and PPT, which could be that VAL and GAN were not completely extractable in LLE and PPT due to plasma binding. VAL is prodrug to GAN, the 2 % OPA treatment would remove the acidic impurities and may stop the conversion of VAL to GAN in plasma and then 5 % methanol treatment would remove impurities and may increases the un-ionization of GAN i.e. the MCX cartridges mechanism played an important role in maximum retention of acidic VAL and basic GAN in SPE method.

The carryover test is very important to know the sample passing from previous sample to next sample in any analysis either from higher or lower concentrations. No carryover was observed in extracted blanks (n=6) after injection of 6 extracted LLOQ (2.04 ng/ml of VAL; 40.41 ng/ml of GAN) and ULOQ (805.35 ng/ml of VAL and 12097.57 ng/ml of GAN) before every injection of blank. Background interference for VAL, GAN and ISs were tested by extracting (n=10) blank plasma and found that there was no significant interference at RT of VAL, GAN and ISs (fig. 2) i.e. as per US FDA guidelines it was <20 % for analyte and <5 % for IS.

pharmaceutical-sciences-valganciclovir-ganciclovir

Figure 2: MRM spectra of valganciclovir and ganciclovir of blank plasma samples
A. blank-valganciclovir, B. blank-valganciclovir D5, C. blankganciclovir and D. blank-ganciclovir D5

The LLOQ level for CC of VAL (2.04 ng/ml) and GAN (40.41 ng/ml) in plasma were successfully quantified with precision and accuracy 7.49 % and 101.23 % for VAL and 3.52 % and 101.19 % for GAN (fig. 3).

pharmaceutical-sciences-spectra-valganciclovir-ganciclovir

Figure 3: MRM spectra of valganciclovir and ganciclovir at LLOQ levels
A. LLOQ-1-valganciclovir, B. LLOQ-1-valganciclovir D5, C. LLOQ QC-01-ganciclovir and D. LLOQ QC-01-ganciclovir D5

ME was tested for the VAL and GAN using selected matrix lots (n=10) at LQC and HQC levels and the results indicated no significant ME on analyte. The mean IS matrix normalized factor (IS NMF) for VAL, GAN were 0.98, 0.92 at LQC and 0.99 and 0.99 at HQC levels. The precession for IS NMF for VAL and GAN were 2.04, 3.98 % at LQC level and 1.68 and 1.68 % at HQC level (IS NMF= peak response area ratio in presence of matrix ions/mean peak response area ratio in absence of matrix ions).

Different independent batches (n=5) were analysed on different days, each batch with zero blank, 10 CC points and 6 replicates of LLOQ, LQC, MQC1, MQC2 and HQC. The concentration ranges for VAL was 2.04 to 805.35 ng/ml and GAL was 40.41 to 12097.57 ng/ml. The correlation co-efficient (r) for each batch was >0.99 (fig. 4). The intraday (n=12) and inter day (n=30) accuracy and precession were within the limits as per regulatory guidelines for VAL and GAN (Table 4). Recovery of VAL and GAN from spiked samples (extracted samples) was at LQC, MQC2 and HQC levels with their aqueous samples (non-extracted samples). SPE gave almost clean extractive of VAL with 90.91 % and GAN with 93.86 % recovery (Table 5).

pharmaceutical-sciences-linearity-valganciclovir-ganciclovir

Figure 4: Concentration-response linearity curves of valganciclovir and ganciclovir

Name of the analyte Nominal Concentration (ng/ml) Mean (SD) Precession (%CV) % Accuracy Mean (SD) Precession (% CV)
Intraday accuracy and precession (n=12)
Valganciclovir LLOQ QC (2.04) 1.86 (0.23) 11.88 94.66 (9.23) 9.75
LQC (6.01) 6.05 (0.28) 4.70 100.56 (4.73) 4.71
MQC1
(125.28)
134.958 (5.07) 3.75 107.73 (4.04) 3.75
MQC2
(377.35)
406.96 (7.63) 1.88 107.84 (2.02) 1.88
HQC (566.56) 608.80 (19.02) 3.12 107.44 (3.36) 3.12
Ganciclovir LLOQ QC
(40.43)
41.89 (2.66) 6.36 103.62 (6.59) 6.36
LQC (121.04) 117.53 (2.38) 2.03 97.10 (1.97) 2.03
MQC1
(1806.56)
1782.99
(54.43)
3.05 98.69 (3.01) 3.05
MQC2
(6021.89)
6029.31
(181.87)
3.02 100.12 (3.02) 3.02
HQC
(9041.88)
8799.88
(320.43)
3.64 97.32 (3.54) 3.64
Inter day accuracy and precession (n=30)
Valganciclovir LLOQ QC (2.04) 2.02 (0.21) 10.43 98.97 (10.32) 10.43
LQC (6.01) 5.91 (0.37) 6.30 98.25 (6.19) 6.30
MQC1
(125.28)
134.845 (3.57) 2.65 107.635 (2.85) 2.65
MQC2
(377.35)
401.60 (8.64) 2.15 106.43 (2.29) 2.15
HQC (566.56) 592.86 (20.12) 3.39 104.63 (3.55) 3.39
Ganciclovir LLOQ QC
(40.43)
41.38 (2.74) 6.63 102.35 (6.78) 6.63
LQC (121.04) 115.42 (3.54) 3.06 95.35 (2.92) 3.06
MQC1
(1806.56)
1711.818
(77.53)
4.53 94.75 (4.29) 4.53
MQC2
(6021.89)
5918.88
(167.46)
2.83 98.28 (2.78) 2.83
HQC
(9041.88)
8761.30
(240.47)
2.74 96.89 (2.66) 2.74

Table 4: Intra day and inter day accuracy and precession of valganciclovir and ganciclovir

  LQC# response MQC2# response HQC# response
Extracted Non-extracted Extracted Non-extracted Extracted Non-extracted
Valganciclovir
Mean 26922.0 30504.2 2086635.0 2123642.8 2611220.8 3028957.8
S.D. 562.32 1208.88 36349.68 78870.33 69648.25 78196.84
C.V (%) 2.09 3.96 1.74 3.71 2.67 2.58
% Recovery 88.26 98.26 86.21
Overall recovery 90.91 %
Ganciclovir
Mean 45327.0 48604.7 2261993.7 2488342.2 3887515.3 3990304.5
S.D. 824.02 1580.09 59409.29 55741.90 66063.77 133590.62
C.V.(%) 1.82 3.25 2.63 2.24 1.70 3.35
% Recovery 93.26 90.90 97.42
Overall recovery 93.86 %

Table 5: Recovery of valganciclovir, ganciclovir and valganciclovir d5, ganciclovir d5 from spiked plasma samples

The results of the DI at 25:75 of VAL and GAN (2495.07 ng/ml of VAL and 38205.11 ng/ml of GAN) were analysed as 6 replicates, which were found to be within the acceptance criteria with precision (1.27) and accuracy (100.08 %) to VAL and precision (1.04) and accuracy (108.05 %) to GAN and the processed sample have nominal concentration within ±15 %.

Stability of VAL and GAN was studied under diverse conditions and the results are summarized in Table 6. VAL and GAN stock solutions were stable at RT for 21 h and spiking samples (bench-top stability) stable at RT for 10 h. The spiked storage samples at –70° were found to be stable after 4 freeze-thaw cycles. VAL and GAN were stable after the processing i.e. wet extract stability at RT and AS at 5° were 51 h and 63 h, respectively. The re-injection stability for the processed sample was 41 h. All the tested conditions for VAL and GAN stability of their CCs and QCs were within the acceptance criteria (±15 % of their nominal concentration).

Name of the stability parameter Valganciclovir Ganciclovir
LQC (6.01 ng/ml) HQC (566.59 ng/ml) LQC (121.04 ng/ml) HQC (9041.88 ng/ml)
mean±SD (% CV) (% nominal concentration) mean±SD (% CV) (% nominal concentration)
Freeze thaw
(4 cycles)
5.61±5.60
(4.57) (93.22)
562.53±17.49
(3.11) (99.28)
116.60±9.75
(8.36) (96.33)
9774.28±579.76
(6.12) (108.10)
Bench top at RT
(10 h 26 min)
5.88±0.21
(3.72) (97.77)
587.97±8.79
(1.50) (103.77)
125.18±1.88
(1.50) (103.42)
8751.63±365.62
(4.18) (96.79)
Short term
(-20±5°)
(2 d 21 h)
5.39±0.33
(6.13) (89.61)
564.86±26.16
(4.63) (99.69)
118.87±8.88
(7.47) (98.21)
9983.81±166.21
(1.66) (110.42)
Wet extract at RT
(51 h 41 min)
5.75±0.13
(2.27) (95.57)
562.69±12.34
(2.19) (99.31)
122.55±6.47
(5.28) (101.25)
9043.98±760.46
(8.41) (100.02)
Auto sampler at 5°
(63 h 2 min)
5.43±0.22
(4.18) (90.30)
563.07±16.43
(2.12) (99.38)
115.82±14.0
(12.1) (95.69)
9681.70±299.27
(3.09) (107.08)
Re-injection
(41 h 31 min)
5.84±0.47
(8.16) (97.06)
606.30±4.38
(0.72) (107.01)
105.71±5.49
(5.20) (87.34)
8898.27±174.16
(1.96) (98.41)

Table 6: Stability of valganciclovir and ganciclovir at different conditions

The integrity of a validated method on long run of study sample analysis was evaluated on long run by processing 40 replicates of LQC, MQC1, MQC2 and HQC samples with freshly prepared CC samples and 6 replicates of each QC samples as total of 192 samples were analysed as single batch. All the processed samples were within the acceptance criteria as their nominal concentration was ±15 % at each QC level.

The validated method was successfully applied to a clinical study on healthy human volunteers (n=6) with 50 mg/ml of 900 mg oral solution dosage at fasting condition. The mean results of drug concentration versus time are shown in figs. 5a (VAL) and 5b (GAN). The maximum concentration (Cmax) of VAL was about 300 ng/ml at maximum time (Tmax) 0.50 h and Cmax of GAN was about 5000 ng/ml at Tmax 1.00 h. The pharmacokinetic parameters were summarized in Table 7. After the study sample analysis, ISR was also carried out because it is important to know the reproducibility of concentration vs. time and is necessary for the approval of drugs by USFDA. The performed ISR analysis samples were within the acceptance (<20 %) variation from their initial values (Table 8).

pharmaceutical-sciences-plasma-valganciclovir-ganciclovir

Figure 5: Plasma concentration vs. time profile of valganciclovir and ganciclovir
Mean concentration of A. valganciclovir and B. ganciclovir from clinical samples was plotted against time equation

Pharmacokinetic parameter Valganciclovir (mean±SD)# Ganciclovir (mean±SD)#
C-max (ng/ml) 303.48±85.15 5193.53±832.68
T-max (h) 0.85±0.47 1.71±0.29
AUC-T (h×ng/ml) 498.07±80.54 26422.75±4462.74
AUC-INF (h×ng/ml) 498.53±80.42 26549.92±4486.83
T-half (h) 1.14±0.40 4.97±0.84
K-el (1/h) 0.66±0.18 0.14±0.02

Table 7: Pharmacokinetic parameters of valganciclovir and ganciclovir

Valganciclovir Ganciclovir
Sample ID# (h) Initial Concent-ration (ng/ml) ISR Concent-ration (ng/ml) % Variability Sample ID (h) Initial Concent-ration (ng/ml) ISR Concent-ration (ng/ml) % Variability
0.83 442.70 390.25 12.59 2.25 4155.89 4000.15 4078.02
4.50 7.550 7.12 5.85 16.00 226.18 198.562 212.372
0.83 312.56 298.54 4.59 1.75 4440.41 4215.85 4328.13
5.00 8.979 7.95 12.06 16.00 251.94 225.369 238.65
2.00 192.53 186.14 3.38 2.00 5516.79 5001.99 5259.39
5.00 8.595 7.56 12.76 16.00 260.21 245.698 252.95
0.67 307.19 287.98 6.46 2.00 4380.02 4100.66 4240.34
4.00 10.97 9.58 13.54 16.00 254.85 232.61 243.73
0.67 214.63 200.01 7.06 1.50 6364.85 6102.75 6233.79
4.00 9.67 8.95 7.73 24.00 124.58 119.258 121.92
0.50 203.67 198.56 2.54 2.00 5636.15 5512.4 5574.27
4.50 9.10 8.95 1.72 16.00 226.76 217.951 222.35

Table 8: Analysis of valganciclovir and ganciclovir in subject samples

Bioanalysis plays a key role in the drug discovery process by providing reliable pharmacokinetic parameters by estimating the test drug concentrations in biological matrices like blood, plasma, and urine[23,24]. Currently the situation of emerging and resistant diseases is prompting the researchers to discover lead drug molecules with broad therapeutic values. These discoveries simultaneously require reliable analytical methods with rapid analysis and accuracy. HIV is most mortality causing disease in the world from mid-20th century and researchers developed few drugs to control the disease and its side effects but till now there is no drug to cure HIV/AIDS. VAL is one of the antiviral drugs effective against CMV infections in HIV/AIDS patients and also used to control CMV infections in organ transplantation condition. VAL is a prodrug of GAN, which inhibits the chain elongation of viral replication[13]. Since the WHO declared VAL as an essential medicine[14] and that VAL received generic approval, it became very essential that fast and reliable methods are available to quantify VAL and GAN in different biological matrices from generic formulations under development to get marketing approval. In an attempt to fill this gap, the current study was taken up to develop a simple and rugged method to evaluate VAL and GAN simultaneously in human plasma, validate it as per USFDA guidelines and to apply this method to determine pharmacokinetic parameters of VAL and GAN.

The developed and validated method is the first method which used deuterated compounds as ISs. Because ISs are very important to obtain high accuracy when LC is coupled with a mass detector and stable isotopelabelled (stable ISs) drugs as ISs help to find possible ME[25]. The earlier reported methods for VAL and GAN used non-isotope drugs as ISs[17,18]. The validated method is found to have very high sensitivity, since the method facilitated quantification of VAL and GAN at 2 ng/ml and 40 ng/ml, respectively with high recovery (>90 %) and low runtime making this method an economic and easy to run method compared to other reported methods[16,19]. The developed and validated method using deuterated IS was found reliable and could be successfully applied to a clinical study to estimate VAL and GAN in human plasma samples quite effectively.

Acknowledgments:

The authors thank AnaCipher CRO, Hyderabad for providing the necessary facilities to complete the research work.

Conflict of interest:

Authors declare no conflicts of interest.

References